Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

Hans-Joachim Schmoll, MD
Published: Tuesday, Oct 10, 2017



Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 


Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x